Publications & Invited Lectures

Publications

o   Thumber NK, Elsbahi H, McGrath C, Christou EAA, Walker S, Naik H, Bintcliffe K, Ibbotson SH, Weatherhead S, Fityan A, Goulden V, Rhodes LE, Rutter KJ, Wagner A, Grattan C, Fassihi H, Ferguson J, Sarkany R, Tziotzios C, Simpson M, McGrath J, McSweeney SM. Characterisation of the clinical and photobiological features of solar urticaria: a United Kingdom multicentre cross-sectional study. Br J Dermatol. 2025 Apr 28:ljaf159. doi: 10.1093/bjd/ljaf159.

o   Boontaveeyuwat E, Fassihi H, Sarkany RPE. 'Actinic Prurigo': A Phrase Describing Four Different Diseases in Four Different Continents: Systematic Review and Analysis. Photodermatol Photoimmunol Photomed. 2025 May;41(3):e70018. doi: 10.1111/phpp.70018.

o   Walburn J, Norton S, Sarkany R, Canfield M, Sainsbury K, McCrone P, Araújo-Soares V, Morgan M, Boadu J, Foster L, Heydenreich J, Mander AP, Sniehotta FF, Wulf HC, Weinman J. A personalized and systematically designed adherence intervention improves photoprotection in adults with xeroderma pigmentosum (XP): results of the XPAND randomized controlled trial. Br J Dermatol. 2025;192:728-737.

o   Giovannini S, Weibel L, Schittek B, Sinnberg T, Schaller M, Lemberg C, Fehrenbacher B, Biesemeier A, Nordin R, Ivanova I, Kurz B, Svilenska T, Berger C, Bourquin JP, Kulik A, Fassihi H, Lehmann A, Sarkany R, Kobert N, van Toorn M, Marteijn JA, French LE, Rocken M, Vermeulen W, Kamenisch Y, Berneburg M. Skin Cancer Induction by the Antimycotic Drug Voriconazole Is Caused by Impaired DNA Damage Detection Due to Chromatin Compaction. J Invest Dermatol. 2024;144:2465-2476.

o   Boontaveeyuwat E, Willis F, Fassihi H, Sarkany RPE.  Successful serial plasmapheresis for solar urticaria, a case report and literature review. J Dermatolog Treat. 2024;35:2350229. doi: 10.1080/09546634.2024.2350229. Epub 2024 Jun 16.

o   Sarkany R, Walburn J, Anderson R, Araujo-Soares V, Boadu J, Canfield M, Foster L, McCrone P, Morgan M, Norton S, Sainsbury K, Weinman J. Development and evaluation of a personalised psychological intervention to improve adherence to photoprotection in adults with Xeroderma Pigmentosum (XP). Southampton (UK): National Institute for Health and Care Research; 2024 Jun.

o   Sarkany RPE, Phillips JD. The clinical management of porphyria cutanea tarda: An update. Liver Int. 2024 Sep;44(9):2191-2196. doi: 10.1111/liv.15980. Epub 2024 May 30.

o   Badja C, Momen S, Koh GCC, Boushaki S, Roumeliotis TI, Kozik Z, Jones I, Bousgouni V, Dias JML, Krokidis MG, Young J, Chen H, Yang M, Docquier F, Memari Y, Valcarcel-Zimenez L, Gupta K, Kong LR, Fawcett H, Robert F, Zhao S, Degasperi A, Kumar Y, Davies H, Harris R, Frezza C, Chatgilialoglu C, Sarkany R, Lehmann A, Bakal C, Choudhary J, Fassihi H, Nik-Zainal S. Insights from multi-omic modeling of neurodegeneration in xeroderma pigmentosum using an induced pluripotent stem cell system. Cell Rep. 2024;43:114243.

o   O'Reilly M, Paolino A, Pathmarajah P, Ferguson J, Smith CH, Sarkany R, Dawe RS, Salam A, Pink AE, Fassihi H, Ibbotson S.  Dupilumab in chronic actinic dermatitis: a retrospective case series. Br J Dermatol. 2024;191:297-299.

o   McSweeney SM, Mounsey S, Arujuna N, Garibaldinos T, Sarkany R, Fassihi H. A single-centre retrospective review of treatment responses and adverse events of thalidomide in patients with inflammatory skin disease. Clin Exp Dermatol. 2024;49:168-170.

o   Garcia-Moreno H, Langbehn DR, Abiona A, Garrood I, Fleszar Z, Manes MA, Morley AMS, Craythorne E, Mohammed S, Henshaw T, Turner S, Naik H, Bodi I, Sarkany RPE, Fassihi H, Lehmann AR, Giunti P. Neurological disease in xeroderma pigmentosum: prospective cohort study of its features and progression. Brain. 2023;146:5044-5059.

o   Fernandez ER, Tamura D, Khan SG, Momen S, Fassihi H, Sarkany R, DiGiovanna JJ, Kraemer KH. Retrospective study of efficacy and adverse events of immune checkpoint inhibitors in 22 xeroderma pigmentosum patients with metastatic or unresectable cancers. Front Oncol. 2023 Oct 25;13:1282823. doi: 10.3389/fonc.2023.1282823. eCollection 2023.

o   Walburn J, Foster L, Araújo-Soares V, Sarkany R, Weinman J, Sainsbury K, Morgan M. Acceptability and influence of a complex personalized intervention on changes in photoprotection behaviours among people with xeroderma pigmentosum. Br J Health Psychol. 2023;28:1113-1131.

o   Fityan A, Aneju GA, Morley AMS, Sarkany R. Ocular protection in congenital erythropoietic porphyria: A potential role for gaming glasses. Photodermatol Photoimmunol Photomed. 2023;39:535-537.

o   McSweeney SM, Kloczko E, Chadha M, Sarkany R, Fassihi H, Tziotzios C, McGrath JA. Systematic review of the clinical characteristics and natural history of solar urticaria. J Am Acad Dermatol. 2023;89:138-140.

o   McSweeney SM, Bintcliffe K, Fassihi H, Sarkany R, Rutkowski C. Cover Image: Local cutaneous refractoriness to sun exposure following omalizumab injections in solar urticaria. Br J Dermatol. 2023;188:e34.

o   Tavabie OD, Fassihi H, Fityan A, Arujuna N, Naik H, Ferguson J, Aluvihare V, Sarkany R. Fibrosis assessment using transient elastography identifies obesity as a risk factor for hepatic fibrosis in erythropoietic protoporphyria. Photodermatol Photoimmunol Photomed. 2023;39:400-402.

o   Sarkany R, Norton S, Canfield M, Morgan M, Foster L, Sainsbury K, Araujo-Soares V, Wulf HC, Weinman J, Walburn J. Identifying the psychosocial predictors of ultraviolet exposure to the face in patients with xeroderma pigmentosum: a study of the behavioural factors affecting clinical outcomes in this genetic disease. J Med Genet. 2022;59:1095-1103.

o   Lawrence KP, Sarkany RPE, Acker S, Herzog B, Young AR. A new visible light absorbing organic filter offers superior protection against pigmentation by wavelengths at the UVR-visible boundary region. J Photochem Photobiol B. 2022;227:112372.

o   Sarkany RPE, Canfield M, Morgan M, Foster L, Johnstone K, Sainsbury K, Araujo-Soares V, Wulf HC, Weinman J, Walburn J, Norton S. Ultraviolet radiation exposure to the face in patients with xeroderma pigmentosum and healthy controls: applying a novel methodology to define photoprotection behaviour. Br J Dermatol. 2022;186:713-720.

o   McSweeney SM, Sarkany R, Fassihi H, Tziotzios C, McGrath JA.
Pathogenesis of solar urticaria: Classic perspectives and emerging concepts. Exp Dermatol. 2022;31:586-593.

o   Boontaveeyuwat E, Steyn M, Rickaby W, Mcfadden JP, Sarkany RPE, Fityan A. Tricyclic antidepressant-induced photosensitivity; A case report and systematic review. Photodermatol Photoimmunol Photomed. 2022;38:112-122.

o   Ibbotson SH, Allan D, Dawe RS, Eadie E, Farr PM, Fassihi H, Fedele F, Ferguson J, Fityan A, Freeman P, Fullerton L, Goulden V, Haque S, Ling TC, Mackay A, McKenna K, Ralph N, Rhodes LE, Sarkany R, Turner D, Ungureanu S, Weatherhead S. Photodiagnostic services in the UK and Republic of Ireland: a British Photodermatology Group Workshop Report. J Eur Acad Dermatol Venereol. 2021;35:2448-2455.

o   Howard L, Birnie A, Sarkany R. Comment on Benzophenone Accumulates over Time from the Degradation of Octocrylene in Commercial Sunscreen Products. Chem Res Toxicol. 2021;34:1944-1945

    • Fajuyigbe D, Douki T, van Dijk A, Sarkany RP, Young AR. Dark cyclobutane pyrimidine dimers are formed in the epidermis of Fitzpatrick skin types I/II and VI in vivo after exposure to solar simulated radiation. Pigment Cell Melanoma Res. 2020 Dec 26. doi: 10.1111/pcmr.12956. Epub ahead of print. PMID: 33369222.
    • Canfield M, Norton S, Walburn J, Morrison-Bowen N, Sainsbury K, Araujo-Soares V, Sarkany R, Weinman J. Facial photoprotection in xeroderma pigmentosum (XP) patients: Validation of a new self-reported questionnaire of adherence. Photodermatol Photoimmunol Photomed. 2020;36:118-125.
    • Harte J, Chapagain A, Sarkany RPE, Chaudhri S. The Case | Bullous eruptions in end-stage renal failure. Kidney Int. 2020;97:1067-1068.
    • Walburn J, Canfield M, Norton S, Sainsbury K, Araújo-Soares V, Foster L, Berneburg M, Sarasin A, Morrison-Bowen N, Sniehotta FF, Sarkany R, Weinman J. Psychological correlates of adherence to photoprotection in a rare disease: International survey of people with Xeroderma Pigmentosum. Br J Health Psychol. 2019;24:668-686
    • Walburn J, Norton S, Sarkany R, Sainsbury K, Araújo-Soares V, Morgan M, Canfield M, Foster L, Heydenreich J, McCrone P, Mander A, Sniehotta FF, Wulf HC, Weinman J. Evaluation of a personalised adherence intervention to improve photoprotection in adults with Xeroderma Pigmentosum (XP): protocol for the trial of XPAND. BMJ Open. 2019;9:e028577. doi: 10.1136/bmjopen-2018-028577.
    • Cohen JI, Manoli I, Dowdell KC, Krogmann TA, Tamura D, Radecki P, Bu W, Turk SP, Liepshutz K, Hornung RL, Fassihi H, Sarkany RP, Bonnycastle LL, Chines PS, Swift AJ, Myers TG, Levoska MA, DiGiovanna JJ, Collins FS, Kraemer KH, Pittaluga S, Jaffe ES. Hydroa vacciniforme-like lymphoproliferative disorder: an EBV disease with a low risk of systemic illness in Caucasians. Blood. 2019 May 7. Doi: 10.1182/blood.2018893750. [Epub ahead of print]
    • Morgan M, Anderson R, Walburn J, Weinman J, Sarkany R. The influence of perceived medical risks and psychosocial concerns on photoprotection behaviours among adults with xeroderma pigmentosum: a qualitative interview study in the UK. BMJ Open. 2019;9:e024445. doi: 10.1136/bmjopen-2018-024445.
    • Lawrence KP, Douki T, Sarkany RPE, Acker S, Herzog B, Young AR. The UV/Visible Radiation Boundary Region (385-405 nm) Damages Skin Cells and Induces "dark" Cyclobutane Pyrimidine Dimers in Human Skin in vivo. Sci Rep. 2018; 8:12722.
    • Fajuyigbe D, Coleman A, Sarkany RPE, Young AR, Schmalwieser AW. Diffuse Reflectance Spectroscopy as a Reliable Means of Comparing Ultraviolet Radiation-induced Erythema in Extreme Skin Colors. Photochem Photobiol. 2018;94:1066-1070.
    • Fajuyigbe D, Lwin SM, Diffey BL, Baker R, Tobin DJ, Sarkany RPE, Young AR. Melanin distribution in human epidermis affords localized protection against DNA photodamage and concurs with skin cancer incidence difference in extreme phototypes. FASEB J. 2018;32:3700-3706.
    • Young AR, Greenaway J, Harrison GI, Lawrence KP, Sarkany R, Douki T, Boyer F, Josse G, Questel E, Monteil C, Rossi AB. Sub-optimal Application of a High SPF Sunscreen Prevents Epidermal DNA Damage in Vivo. Acta Derm Venereol. 2018;98:880-887.
    • Sainsbury K, Vieira R, Walburn J, Sniehotta FF, Sarkany R, Weinman J, Araujo-Soares V. Understanding and predicting a complex behavior using n-of-1 methods: Photoprotection in xeroderma pigmentosum. Health Psychol. 2018;37:1145-1158.
    • Fityan A, McGibbon D, Fassihi H, Sarkany R. Paediatric solar urticaria: a case series. Br J Dermatol. 2018;178:1453-1454.
    • Chee SN, Novakovic L, Fassihi H, Garibaldinos T, Sarkany R Chronic actinic dermatitis: successful treatment with psoralen-ultraviolet A photochemotherapy. Br J Dermatol. 2018;178:e189-e190.
    • Tewari A, Fityan A, Fassihi H, Sarkany R. Solar urticaria developing in patients with erythropoietic protoporphyria: a clue to the pathogenesis of solar urticaria? Br J Dermatol. 2018;178:567-568.
    • Abeti R, Zeitlberger A, Peelo C, Fassihi H, Sarkany RPE, Lehmann AR, Giunti P. Xeroderma pigmentosum: overview of pharmacology and novel therapeutic strategies for neurological symptoms. Br J Pharmacol. 2018 . doi: 10.1111/bph.14557. [Epub ahead of print] Review.
    • Trokoudes D, Banerjee P, Fityan A, Sarkany R, White IR, White JM, McFadden JP. Photoaggravated contact dermatitis caused by methylisothiazolinone. Contact Dermatitis. 2017;76:303-304.
    • Walburn J, Sarkany R, Norton S, Foster L, Morgan M, Sainsbury K, Araújo-Soares V, Anderson R, Garrood I, Heydenreich J, Sniehotta FF, Vieira R, Wulf HC, Weinman J. An investigation of the predictors of photoprotection and UVR dose to the face in patients with XP: a protocol using observational mixed methods. BMJ Open. 2017;7:e018364.
    • Sebaratnam DF, Sarkany RPE, Fassihi H. A 'spot' diagnosis. Arch Dis Child Educ Pract Ed. 2017;102:220-221
    • Garcia-Moreno H, Fassihi H, Sarkany RPE, Phukan J, Warner T, Lehmann AR, Giunti P. Xeroderma pigmentosum is a definite cause of Huntington's disease-like syndrome. Ann Clin Transl Neurol. 2017;5:102-108.
    • Momen S, Sarkany R. Are very high cumulative doses of narrowband UVB safe in vitiligo?. Photodermatol Photoimmunol Photomed. 2017;33: 220-221.
    • Sethi M, Haque S, Fawcett H, Wing JF, Chandler N, Mohammed S, Frayling IM, Norris PG, McGibbon D, Young AR, Sarkany RP, Lehmann AR, Fassihi H. A Distinct Genotype of XP Complementation Group A: Surprisingly Mild Phenotype Highly Prevalent in Northern India/Pakistan/Afghanistan. J Invest Dermatol. 2016;136:869-72.
    • Fityan A, Fassihi H, Sarkany R. Congenital erythropoietic porphyria: mild presentation with late onset associated with a mutation in the UROS gene promoter sequence. Clin Exp Dermatol. 2016;41:953-954
    • Tewari A, Grys K, Kollet J, Sarkany R, Young AR. Upregulation of MMP12 and its activity by UVA1 in human skin: potential implications for photoaging. J Invest Dermatol. 2014;134:2598-609.
    • Tewari A, Grage MM, Harrison GI, Sarkany R, Young AR. UVA1 is skin deep: molecular and clinical implications. Photochem Photobiol Sci. 2013;12:95-103.
    • Sethi M, Lehmann AR, Fawcett H, Stefanini M, Jaspers N, Mullard K, Turner S, Robson A, McGibbon D, Sarkany R, Fassihi H. Patients with xeroderma pigmentosum complementation groups C, E and V do not have abnormal sunburn reactions. Br J Dermatol. 2013;169:1279-87.
    • Kashiyama K, Nakazawa Y, Pilz DT, Guo C, Shimada M, Sasaki K, Fawcett H, Wing JF, Lewin SO, Carr L, Li TS, Yoshiura K, Utani A, Hirano A, Yamashita S, Greenblatt D, Nardo T, Stefanini M, McGibbon D, Sarkany R, Fassihi H, Takahashi Y, Nagayama Y, Mitsutake N, Lehmann AR, Ogi T. Malfunction of Nuclease ERCC1-XPF Results in Diverse Clinical Manifestations and Causes Cockayne Syndrome, Xeroderma Pigmentosum, and Fanconi Anemia. Am J Hum Genet. 2013;92:807-19.
    • Gonçalo M, Ferguson J, Bonevalle A, Bruynzeel DP, Giménez-Arnau A, Goossens A, Kerr A, Lecha M, Neumann N, Niklasson B, Pigatto P, Rhodes LE, Rustemeyer T, Sarkany R, Thomas P, Wilkinson M. Photopatch testing: recommendations for a European photopatch test baseline series. Contact Dermatitis. 2013;68:239-43.
    • Kerr AC, Ferguson J, Attili SK, Beattie PE, Coleman AJ, Dawe RS, Eberlein B, Goulden V, Ibbotson SH, Menage H du P, Moseley H, Novakovic L, Walker SL, Woods JA, Young AR, Sarkany RP . Ultraviolet A1 phototherapy: a British Photodermatology Group workshop report. Clin Exp Dermatol. 2012 37:219-26.
    • Sarkany R. Congenital erythropoietic porphyria: bringing evidence-based practice to a rare disease. Br J Dermatol. 2012;167:709.
    • Agius E and Sarkany R. Thalidomide in 2nd Edition Handbook of Systemic Drug Treatment in Dermatology, Manson Publishing, 2012.
    • Sarkany RP. Photopatch testing comes of age. Br J Dermatol. 2012 166:912-3. (Commentary)
    • Stein PE, Badminton MN, Barth JH, Rees DC, Sarkany R, Stewart MF, Cox TM. Acute intermittent porphyria: fatal complications of treatment (lesson of the month) Clinical Medicine, 12: 293-4 (2012)
    • Tewari A, Marsden J, Naik H, Benton EC, Sarkany R. Oral cholestyramine is not an effective treatment for uncomplicated erythropoietic protoporphyria. J Am Acad Dermatol. 2012;67:1383-4.
    • Tewari A, Sarkany RP, Young AR. UVA1 induces cyclobutane pyrimidine dimers but not 6-4 photoproducts in human skin in vivo. J Invest Dermatol. 2012 132:394-400.
    • Tewari A, Lahmann C, Sarkany R, Bergemann J, Young AR.Human erythema and matrix metalloproteinase-1 mRNA induction, in vivo, share an action spectrum which suggests common chromophores. Photochem Photobiol Sci. 2012;11:216-23.
    • Byrne M, Stefanato CM, Sarkany R. A photosensitive pseudolymphomatous eruption. Actinic reticuloid (AR). Clin Exp Dermatol. 2012;37:203-4
    • Penny H, Frame S, Dickinson F, Garrett G, Young AR, Sarkany R, Chitalia N, Hampson G, Goldsmith D. Determinants of vitamin D status in long-term renal transplant patients. Clin Transplant. 2012 26:E617-23.
    • Sarkany PE, et al. Erythropoietic Uroporphyria Associated with Myeloid Malignancy Is Likely Distinct from Autosomal Recessive Congenital Erythropoietic Porphyria. Journal of Investigative Dermatology 131, 1172-1175 (2011).
    • Jiun-Yit Pan and Robert P.E. Sarkany (2011). A Comparison of NB-UVB and PUVA in the Treatment of Vitiligo, Vitiligo - Management and Therapy, Kelly KyungHwa Park and Jenny Eileen Murase (Ed.), ISBN: 978-953-307-731-4, InTech, Available from: http://www.intechopen.com/articles/show/title/a-comparison-of-nb-uvb-and-puva-in-the-treatment-of-vitiligo
    • Natkunarajah J, Gordon K, Chow J, Sarkany R, Millington GW, Marsden RA. Photoaggravated Sweet's syndrome. Clin Exp Dermatol. 2010;35:18-9.
    • Almaani N, Robson A, Sarkany R, Griffiths WA. Erythema gyratum repens associated with pityriasis rubra pilaris. Clin Exp Dermatol. 2011;36:161-4.
    • Sarkany R. Clinical implications of advances in understanding the inheritance of erythropoietic protoporphyria. Br J Dermatol. 2010;162:1156-7.
    • Abbott RA, Calonje E, Grattan CE, Kurwa H, Sarkany RP. Yellow papules and plaques on the face of a young girl. Clin Exp Dermatol. 2009;34:745-6.
    • Akhras V, Sarkany R, Walsh S, Hyde N, Marsden RA. Superficial granulomatous pyoderma treated preoperatively with infliximab. Clin Exp Dermatol. 2009;34:183-5.
    • Wain EM, Mellerio JE, Stefanato CM, Sarkany R. Generalized pustular eruption in a 5-year-old boy. Clin Exp Dermatol. 2008;33:79-80.
    • Jong CT, Finlay AY, Pearse AD, Kerr AC, Ferguson J, Benton EC, Hawk JL, Sarkany RP, McMullen E, Rhodes LE, Farr PM, Anstey AV.. The quality of life of 790 patients with photodermatoses. Br J Dermatol. 2008;159:192-7.
    • Coleman A, Sarkany R, Walker S. Clinical ultraviolet dosimetry with a CCD monochromator array spectroradiometer. Phys Med Biol. 2008;53:5239-55.
    • Fassihi H, Sarkany R. TL01 therapy for vitiligo. Brit Med J 334:1064 2007
    • Ross GL, Chong H, Collyns T, Gascoyne-Binzi DM, Sarkany RP. Lichen scrofulosorum caused by Mycobacterium szulgai: a new cause of a tuberculide reaction. Br J Dermatol. 2007;156:586-7
    • Crouch R, Akhras V, Sarkany R. Schnitzler's syndrome: successful treatment with anakinra. Australas J Dermatol. 2007;48:178-81.
    • Sarkany RPE, Ross G, Willis F. Acquired Erythropoietic protoporphyria as a result of myelodysplasia causing loss of chromosome 18. Br J Dermatol. 155:464-6 (2006).
    • Peters T and Sarkany RPE. Porphyria for the General Physician. Clin Med 5:275-281 (2005)
    • Haydar AA, Hujairi N, Chowdhury P, Pattison J, Deacon A, Sarkany R, Goldsmith DJ. What's in a blister? A diagnostic twister. Nephrol Dial Transplant. 2004;19:1321-2.
    • Morris S, Elder G, Hawk J, Sarkany RPE. Ferrochelatase gene polymorphism analysis for accurate genetic counselling in erythropoietic protoporphyria. Br J Dermatol. 147:572-4 (2002)
    • Sarkany RPE. A memorable patient: a nasty surprise. Clin Exp Dermatol. 27:537-8 (2002)
    • Sarkany R.P.E. Erythropoietic Protoporphyria (EPP) at 40: where are we now? Photodermatol Photoimmunol Photomed 18:147-52 (2002)
    • Sarkany R.P.E. The management of porphyria cutanea tarda. Clin Exp Dermatol 26:225-232 (2001)
    • Sarkany RPE. The porphyrias: a practical guide. Dermatology in Practice 9:6-9 (2001)
    • Sarkany R.P.E. Porphyria: from Sir Walter Raleigh to molecular biology. Rheumaderm: current issues in rheumatology and dermatology. Ed. Mallia C and Uitto J. Advances in Experimental Medicine and Biology 455: 235-241 (1999)
    • Sarkany RPE, Anstey A, Diffey BL et al. Home phototherapy: report on a workshop of the British Photodermatology Group, December 1996. Brit J Dermatol 140:195-199 (1999)
    • Cox TM, Alexander GJM and Sarkany RPE. Protoporphyria. Seminars in Liver Disease; 18: 85-93 (1998)
    • Sarkany RPE, Monk BE, Handfield-Jones SE. Telangiectasia macularis eruptiva perstans: a case report and review of the literature. Clin. Exp. Dermatol. 23: 28-39 (1998)
    • Sarkany RPE, Burrows NP, Grant JW, Pye RJ and Norris PG. The pustular eruption of ulcerative colitis: a variant of Sweet’s syndrome? Brit J Dermatol 138:365-6 (1998).
    • Sarkany RPE and Cox TM. Liver failure in erythropoietic protoporphyria. J. Am. Acad. Dermatol. 34: 540-1 (1996)
    • Sarkany RPE. The inheritance of human erythropoietic protoporphyria. MD Thesis, University of London, 1995.
    • Sarkany RPE and Cox TM. Autosomal recessive erythropoietic protoporphyria: a syndrome of severe photosensitivity and hepatic failure. Quart. J. Med. 88: 541-49 (1995)
    • Sarkany RPE. The molecular genetics of erythropoietic protoporphyria. Current Opinion in Dermatology 219-224 (1995).
    • Sarkany RPE, Whitcombe DM, Cox TM. Molecular characterization of a ferrochelatase gene defect causing anomalous RNA splicing in Erythropoietic Protoporphyria. J. Invest. Dermatol. 102: 481-4 (1994)
    • Sarkany RPE, Alexander GJMA, Cox TM. Recessive inheritance of Erythropoietic Protoporphyria with liver failure. The Lancet 343: 1394-1396 (1994)
    • Sarkany RPE and Norris PG. Hepatic complications of erythropoietic protoporphyria. Brit. J. Dermatol. 130: 258 (1994)
    • Sarkany RPE and Moreland BH. Enhancement of the autocatalytic activation of trypsinogen to trypsin by bile and bile acids. Biochim. Biophys. Acta 839: 262-267 (1985)

Invited Lectures

 

    • ‘Common Misconceptions in Photodermatology’. Joint lecture with Dr. Fassihi. St John’s Dermatological Society Meeting, London, 2025.
    • ‘The inherited photodermatoses: Recent advances in the Porphyrias and Xeroderma Pigmentosum.’ Guest Lecture. The 34th Annual Meeting of the Photodermatology Society. Orlando, 2025
    • ‘Porphyrias and metabolic photosensitivity.’ Annual American Academy of Dermatology Conference. Orlando, 2025
    • ‘Photosensitivity in the cutaneous porphyrias: pathogenesis and photoprotection’. British and Irish Porphyria Network Annual Conference. Cardiff, 2025
    •  
    • ‘Photoprotection in real life: the psychology of protecting the skin against ultraviolet’. British Medical Dermatology Society. Virtual, 2024
    • ‘Liver fibroscanning in 132 EPP patients of the liver to identify hepatic fibrosis.’ International Congress on Porphyrins and Porphyrias (ICPP). Pamplona, 2024.
    • ‘The clinical consequences of oxidative and non-oxidative ultraviolet-induced processes in the skin.’ 11th International Conference on Oxidative Stress in Skin Biology and Medicine. Greece, 2024
    • Ian Magnus Memorial Lecture: ‘Insights in Photodermatology from studying the Porphyrias and DNA repair disorders'. European Society for Photodermatology, Berlin 2023.
    • ‘Cases from the Photobiology Clinic’ . Joint lecture with Dr. Fassihi. British Association of Dermatologists Annual Conference. Liverpool, 2023
    • ‘Specialised advanced care for Xeroderma Pigmentosum’ and ‘Addressing challenges with adherence to photoprotection’. Skin Cancer Foundation of South Africa, 10th Skin Cancer Update Conference. Virtual, 2023
    • ‘Why do some XP patients find it harder to photoprotect than others, and how can they be helped to protect better?’ European XP Society. Milan, 2022.
    • ‘Mechanisms of UV-induced damage in the skin and the challenge of photoprotection.’ 10th International Conference on Oxidative Stress in Skin Biology and Medicine. Greece, 2022
    • ‘The Clinical Management of Porphyria Cutanea Tarda: an update’. International Congress on Porphyrins and Porphyrias (ICPP). Sofia, 2022
    • ‘A new methodology to objectively estimate ultraviolet exposure to the face over a prolonged period. Results from its use in patients with xeroderma pigmentosum (XP) and in healthy subjects.’ British Photodermatology Group. Glasgow, 2022
    • ‘Making sense of the porphyrias.’ British Association of Dermatologists Annual Conference (SAS Section). Glasgow, 2022
    • ‘Managing The Photosensitive Patient’ and ‘Making Sense Of The Porphyrias’. Dermedecon International Conference. Dubai, 2022
    • ‘Photoprotection in real life: the psychology of protecting the skin against ultraviolet’. Guest Lecture, Scottish Dermatology Society Annual Conference. Dundee, 2022
    • ‘Photodermatology and Primary Care’. PULSE National GP Conference. Virtual 2022
    • ‘Photosensitivity, Phototoxicity and Porphyria’. British and Irish Porphyria Network Annual Conference. Dundee, 2022
    • ‘The Psychological basis of photoprotective behaviour in Xeroderma Pigmentosum:  implications for improving photoprotection in other patient groups.’ European Society of Photobiology Annual Conference. Virtual 2021.
    • ‘Development of a validated self-report questionnaire of facial photoprotection in Xeroderma Pigmentosum (XP).’ British Photodermatology Group. Virtual 2021
    • ‘Cases from the Photodermatology Clinic’. British Association of Dermatologists Annual Conference (SAS Section). Virtual 2021
    • ‘Porphyria Cutanea tarda’. Joint lecture with Prof. Stolzel. EPNET Webinar Series, Virtual 2021
    • ‘Seven cases from the Photodermatology Clinic.’ Joint lecture with Drs. Ferguson and Fassihi. St John’s Dermatological Society Meeting, Virtual 2021.
    • ‘The EXPS’. European Academy of Dermatovenereology Annual Conference, Virtual, 2020
    • Photoprotection, UV and Covid-19. Royal College of Physicians, Virtual, 2020.
    • Dermatology Team of the Year: the XP team. British Association of Dermatologists Annual Conference. Liverpool, 2019.
    • The NIHR Xeroderma Pigmentosum (XP) study: detailed investigation of photoprotection behaviours in XP patients, and of the psychosocial factors causing these behaviours. British Association of Dermatologists Annual Conference. Liverpool, 2019.
    • The Sun and the Skin. Dermschool Annual Conference. Liverpool, 2019.
    • The Bullous Porphyrias. The Medical Dermatology Society. Royal College of Physicians. London, 2019;
    • Understanding and improving photoprotection behavior in Xeroderma Pigmentosum. International Symposium on Xeroderma Pigmentosum and other Nucleotide Excision Repair Disorders Downing College. Cambridge, 2019
    • Making sense of the porphyrias. Primary Care Dermatology Society, Stratford-on-Avon, 2019.
    • Photoprotection: psychological factors and beyond. European Society for Photodermatology. Madrid, 2019.
    • EPP: background and update. British and Irish Porphyria Network. Dublin, 2019.
    • ‘The Sun and the Skin’ and ‘Systemic Diseases and the Skin’. Royal College of Physicians’ Conference ‘General Medicine for the Physician’. Cyprus, 2019.
    • Update in the photodermatoses and ultraviolet. ‘Barcelona International Conference’. Barcelona, 2018.
    • What’s new in Photosensitivity and photoprotection. Royal College of Physicians. London, 2018.
    • Therapies for EPP. British and Irish Porphyria Network. Birmingham, 2018.
    • The sun and the skin. Primary Care Dermatology Society. London, 2018.
    • Photosensitivity: Is it lupus? British Society of Rheumatology Annual Conference. Birmingham, 2017.
    • Pan-European study of photoprotection in XP: results. European XP Society. Geneva, 2017.
    • Gerald Levene Oration. Photosensitivity and Lupus. Royal Society of Medicine. London, 2017.
    • What’s new in porphyria: a personal view. British Photodermatology Group Annual Symposium, Liverpool 2017.
    • Photoprotection: What should we be telling our patients? British Association of Dermatologists Annual Conference. Birmingham, 2016.
    • Advances in Xeroderma Pigmentosum. International Symposium on rare skin disorders. Madrid, 2016.
    • Cutaneous Porphyrias. World Congress of Dermatology, Vancouver 2015.
    • Protoporphyria: new developments and novel treatment approaches. Association for Clinical Biochemistry and Laboratory Medicine Annual Conference. Cardiff 2015.
    • XP and DNA Repair: the National Service. BAD Dermatology and Genetic Medicine Society Annual Symposium. Glasgow 2014.
    • ‘Genophotodermatoses’ and ‘The Cutaneous Porphyrias’. European Society for Photodermatology, Dublin 2014.
    • ‘UK National XP service’. International Symposium on XP and diseases of DNA repair. Kobe, Japan, 2014.
    • A full Teaching Course (11 lectures). Estonian Society for Dermatovenerologists Annual Conference. Tallinn, 2014.
    • The Cutaneous porphyrias. Danish Dermatological Society Annual Conference, Vejle, Denmark 2013.
    • The skin in porphyria: clinical clues to mechanisms. World Congress of Porphyrias.  Lucerne, 2013.
    • Systemic therapy in the Photodermatoses. UK Medical Dermatology Society Annual Meeting. Liverpool, 2013.
    • Managing the photogenodermatoses in children. British Paediatric Dermatology Group Annual Meeting. Liverpool, 2013.
    • The Cutaneous porphyrias. Dutch and Flemish Dermatological Society Annual Conference. Antwerp, 2012.
    • Photogenodermatoses. European Academy of Dermatovenereology Spring Meeting.  Verona 2012.
    • Photogenodermatoses. British Photodermatology Group Annual Meeting, 2012.
    • Differential diagnosis of cutaneous porphyrias. Porphyrins and Porphyrias World Congress. Cardiff 2011.
    • New Developments in Xeroderma Pigmentosum. European Academy of Dermatovenereology Annual Conference. Lisbon, 2011.
    • Xeroderma Pigmentosum: the destructive power of ultraviolet. British Association of Dermatologists' Annual Conference. London, 2011.
    • Porphyria for the Dermatologist. European Academy of Dermatovenereology Annual Conference . Gothenburg, 2010.
    • Phototherapy in cutaneous T Cell Lymphoma. 10th International Congress of Dermatology. Prague, 2009.
    • Management of the Cutaneous Porphyrias. European Academy of Dermatovenereology,
    • What’s new in EPP? International Congress of Photobiology. Dusseldorf, 2009.
    • Clinical Management of the porphyrias.  American Academy of Dermatology 2008 (San Antonio) and 2007 (Washington).
    • ‘The epidemiology of the porphyrias’. British Epidermoepidemiology Society meeting, St. Andrews, 2006
    • ‘The management of the cutaneous porphyrias’. European Academy of Dermatovenereology Photodermatology workshop, Rhodes, 2006.
    • Everything you ever wanted to know about porphyria but were afraid to ask. British Photodermatology Group meeting, Glasgow, 2005
    • ‘What’s new in the cutaneous porphyrias’ and ‘The pathogenesis of photosensitivity in the porphyrias’. European Academy of Dermatovenereology. London, 2005.
    • A practical guide to Porphyria for the Dermatologist’ and ‘The management of porphyria cutanea tarda’. European Academy of Dermatovenereology Spring Conference. Florence 2004.
    • Update in the genetics of erythropoietic protoporphyria. World congress of Dermatology. Paris 2002
    • Investigating the porphyrias. Annual UK Dermatology course for Consultants. London 2002
    • The cutaneous porphyrias: clinical aspects. Royal College of Pathologists. London,  2001
    • Update on the diagnosis and management of porphyria cutanea tarda. British Association of Dermatologists' Annual Meeting. Cardiff ,2001.
    • The porphyrias: from Sir Walter Raleigh to molecular biology. Royal College of Physicians. London, 2000
    • The porphyrias: genetic and clinical presentation and management. Scottish Dermatological Society. Royal College of Physicians and Surgeons. Glasgow, 1999
    • The pathogenesis of erythropoietic protoporphyria. Tetrapyrrole Discussion Group Annual Meeting. London, 1997.
    • Porphyria: from Sir Walter Raleigh to molecular biology. International Rheumaderm Conference. Malta, 1997.

Page last reviewed: 14 July 2025
Page created: 30 April 2025